[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595380":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":25,"locations":11,"responsibleParty":31,"collaborators":11,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":11,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":11,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":11,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"combination therapy of Mosunetuzumab and Tislelizumab","EXPERIMENTAL",null,[13,14],"Drug: Mosunetuzumab","Drug: Tislelizumab",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","Mosunetuzumab","* Cycle 1: Day 1: 1 mg; Day 8: 2 mg; Day 15: 30 mg\n* Cycles 2-8: 30 mg every 3 weeks\n* Cycles 9-17: 30 mg every 3 weeks (if applicable） A treatment cycle is 21 days. Patients achieving complete remission (CR) by cycle 8 will stop treatment, while those with partial response (PR) or stable disease (SD) may continue up to 17 cycles or until disease progression or intolerable toxicity occurs.",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"Tislelizumab","\\- Cycles 2-8: 200 mg IV every 3 weeks",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Huilai Zhang","CONTACT","+86-18622221228","huilaizhangtz@163.com",{"type":32,"investigatorFullName":27,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Director of lymphoma department","100595380","phase-2-a-multicenter-single-arm-open-label-phase-ii-trial-of-mosunetuzumab-in-combination-with-tislelizumab-for-rr-fl-100595380",false,"NCT07031700","A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r\u002Fr FL","A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for Relapsed\u002FRefractory Follicular Lymphoma (r\u002Fr FL)","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Age ≥18 years.\n3. Histologically confirmed relapsed\u002Frefractory follicular lymphoma (r\u002Fr FL).\n4. Received at least two prior systemic therapies, including anti-CD20 monoclonal antibody therapy.\n5. ECOG performance status 0-1.\n6. Expected survival ≥12 weeks.\n7. Measurable disease (longest diameter \\>1.5 cm).\n8. Adequate organ function:\n\n   * Hepatic function: Total bilirubin ≤1.5×ULN; AST\u002FALT ≤3×ULN.\n   * Hematologic function: ANC ≥1.5 × 10⁹\u002FL; Platelets ≥75,000\u002FμL; Hemoglobin ≥10.0 g\u002FdL.\n   * Renal function: Serum creatinine ≤1.5×ULN or CrCl ≥50 mL\u002Fmin (Cockcroft-Gault formula).\n9. Women of childbearing potential must have a negative serum pregnancy test and agree to use contraception.\n\nExclusion Criteria:\n\n1. Inability to comply with study hospitalization and restrictions.\n2. Active infections (including tuberculosis) or immunocompromised status.\n3. Prior history of severe hypersensitivity to similar agents.\n4. CNS involvement of lymphoma.\n5. Pregnant or breastfeeding women.\n6. Uncontrolled comorbid conditions, including cardiovascular or autoimmune diseases.\n7. Receipt of live attenuated vaccines within 4 weeks before enrollment.\n8. Use of systemic immunosuppressants within 2 weeks prior to first dose.\n9. History of drug or alcohol abuse in the past 12 months.\n10. Any condition deemed inappropriate for study participation by the investigator.","ALL","18 Years",{"count":44,"type":45},22,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","This is a multicenter, single-arm, open-label, investigator-initiated, phase II clinical trial designed to evaluate the feasibility, efficacy, and safety of Mosunetuzumab in combination with Tislelizumab in patients with relapsed\u002Frefractory follicular lymphoma (r\u002Fr FL).",[51],"Relapsed\u002FRefractory Follicular Lymphoma","NOT_YET_RECRUITING","2025-06-12",{"date":55,"type":56},"2025-06-22","ACTUAL",{"date":58,"type":45},"2025-07-01",{"date":60,"type":45},"2027-07-30",{"name":5,"class":6}]